Archives of Oral Biology
Volume 49, Issue 2 , Pages 133-142 , February 2004

Soluble tumour necrosis factor receptors in synovial fluids from temporomandibular joints with painful anterior disc displacement without reduction and osteoarthritis

,Accepted 22 July 2003.

References 

  1. Ali AM, Sharawy MM. Histopathological changes in rabbit craniomandibular joint associated with experimentally induced anterior disk displacement (ADD). J. Oral Pathol. Med. 1994;23:364–374
  2. Stegenga B. Osteoarthritis of the temporomandibular joint organ and its relationship to disc displacement. J. Orofac. Pain. 2001;15:193–205
  3. Aggarwal BB, Natarajan K. Tumour necrosis factors: developments during the last decade. Eur. Cytokine Netw. 1996;7:93–124
  4. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 1986;322:547–549
  5. Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum. 1990;33:542–552
  6. Mitchell PG, Cheung HS. Tumour necrosis factor alpha and epidermal growth factor regulation of collagenase and stromelysin in adult porcine articular chondrocytes. J. Cell. Physiol. 1991;149:132–140
  7. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990;33:305–315
  8. Westacott CI, Whicher JT, Barnes IC, Thompson D, Swan AJ, Dieppe PA. Synovial fluid concentration of five different cytokines in rheumatic diseases. Ann. Rheum. Dis. 1990;49:676–681
  9. Di Giovine FS, Nuki G, Duff GW. Tumour necrosis factor in synovial exudates. Ann. Rheum. Dis. 1988;47:768–772
  10. Takahashi T, Kondoh T, Fukuda M, Yamazaki Y, Toyosaki T, Suzuki R. Proinflammatory cytokines detectable in synovial fluids from patients with temporomandibular disorders. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1998;85:135–141
  11. Nordahl S, Alstergren P, Kopp S. Tumour necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J. Oral Maxillofac. Surg. 2000;58:525–530
  12. Fu K, Ma X, Zhang Z, Chen W. Tumour necrosis factor in synovial fluid of patients with temporomandibular disorders. J. Oral Maxillofac. Surg. 1995;53:424–426
  13. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 1996;334:1717–1725
  14. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan CF. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor: comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J. Biol. Chem. 1991;266:18846–18853
  15. Ohe H, Takashiba S, Naruishi K, et al.  Tumour necrosis factor-alpha (TNF-alpha)-induced and interleukin-1 beta (IL-1 beta)-induced shedding of TNF receptors from gingival fibroblasts. J. Interferon Cytokine Res. 2000;20:1077–1082
  16. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 1995;38:151–160
  17. Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs. 1998;55:613–620
  18. Alaaeddine N, DiBattista JA, Pelletier JP, et al.  Osteoarthritic synovial fibroblasts possess an increased level of tumor necrosis factor-receptor 55 (TNF-R55) that mediates biological activation by TNF-alpha. J. Rheumatol. 1997;24:1985–1994
  19. Rooney M, Varsani H, Martin K, Lombard PR, Dayer JM, Woo P. Tumour necrosis factor alpha and its soluble receptors in juvenile chronic arthritis. Rheumatology (Oxford). 2000;39:432–438
  20. Pisetsky DS. Tumour necrosis factor blockers in rheumatoid arthritis. N. Engl. J. Med. 2000;342:810–811
  21. Andreas MR. New indications for treatment of chronic inflammation by TNF-blockade. Am. J. Med. Sci. 2003;325:75–92
  22. Kanyama M, Kuboki T, Kojima S, et al.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids of patients with temporomandibular joint osteoarthritis. J. Orofac. Pain. 2000;14:20–30
  23. Orsini MG, Kuboki T, Terada S, Matsuka Y, Yatani H, Yamashita A. Clinical predictability of temporomandibular joint disc displacement. J. Dent. Res. 1999;78:650–660
  24. Matsuka Y, Itoh S, Minakuchi H, Kuboki T, Yamashita A. Validity of questionnaire for epidemiological studies on symptoms of temporomandibular disorders. J. Jpn. Soc. TMJ. 1997;9:80–91
  25. Shafer DM, Assael L, White LB, Rossomando EF. Tumour necrosis factor-alpha as a biochemical marker of pain and outcome in temporomandibular joints with internal derangements. J. Oral Maxillofac. Surg. 1994;52:786–791
  26. Emshoff R, Puffer P, Rudisch A, Gassner R. Temporomandibular joint pain: relationship to internal derangement type, osteoarthrosis, and synovial fluid mediator level of tumor necrosis factor-alpha. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2000;90:442–449
  27. Sandler NA, Buckley MJ, Cillo JE, Braun TW. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular join internal derangements. J. Oral Maxillofac. Surg. 1998;56:534–543
  28. Segami N, Miyamaru M, Nishimura M, Suzuki T, Kaneyama K, Murakami K. Does joint effusion on T2 magnetic resonance images reflect synovitis? Part 2. Comparison of concentration levels of proinflammatory cytokines and total protein in synovial fluid of the temporomandibular joint with internal derangements and osteoarthrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2002;94:515–521
  29. Kaneyama K, Segami N, Nishimura M, Suzuki T, Sato J. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders. Br. J. Oral Maxillofac. Surg. 2002;40:418–423
  30. Girardin E, Roux-Lombard P, Grau GE, et al.  Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology. 1992;76:20–23
  31. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumour necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 1992;89:4845–4849
  32. Feldmann M. What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?. Int. Arch. Allergy Immunol. 1996;111:362–365
  33. Alsalameh S, Mattka B, Al-Ward R. Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor. J. Rheumatol. 1999;26:645–653
  34. Prieur ARM, Oux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev. Rhum. Engl. Ed. 1996;63:163–170
  35. Kuboki T, Hattori T, Mizushima T, et al.  Detection of specific antibodies against human cultured chondrosarcoma (HCS-2/8) and osteosarcoma (Saos-2) cells in the serum of patients with osteoarthritis of the temporomandibular joint. Arch. Oral Biol. 1999;44:403–414
  36. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. 1999;58:165–169
  37. Kacena MA, Merrel GA, Konda SR, Wilson KM, Xi Y, Horowitz MC. Inflammation and bony changes at the temporomandibular joint. Cells Tissues Organs. 2001;169:257–264

☆ A preliminary report was presented at the General Session and Exhibition of the Japanese Association of Dental Research, Matsudo, Chiba, Japan, 2000.

PII: S0003-9969(03)00203-6

doi: 10.1016/j.archoralbio.2003.07.001

Archives of Oral Biology
Volume 49, Issue 2 , Pages 133-142 , February 2004

Article Tools

* Image Usage & Resolution